Search reports, ask a question, or jump to a page.
The problem
Intervention: Peanut oral immunotherapy with low-dose initiation and slow up-dosing, with longitudinal monitoring of basophil activation and sIgE/sIgG4 as possible biomarkers
Who it was tested with: 32 peanut-allergic children: 16 with high Ara h 2-sIgE (≥40 kU/L) and 16 with lower Ara h 2-sIgE.
The same group is measured before the intervention and again afterwards, with a baseline and an endline and sometimes a midline. Change is visible, but other causes cannot be ruled out.
"Thirty-two peanut-allergic children underwent pOIT, including 16 with high and 16 with lower Ara h 2-sIgE." All children received the treatment and were followed over time with no untreated comparison group, so this is a pre-post design.
Small sample, no comparison group without treatment, and exploratory biomarker analyses that need prospective validation. Results are not shown to apply beyond this clinical setting.
Across countries and designs
1 study · 1 country
